Pfizer Inc. (NYSE:PFE) Shares Sold by Matrix Asset Advisors Inc. NY

Matrix Asset Advisors Inc. NY cut its position in Pfizer Inc. (NYSE:PFE) by 2.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 291,405 shares of the biopharmaceutical company’s stock after selling 5,851 shares during the period. Matrix Asset Advisors Inc. NY’s holdings in Pfizer were worth $8,433,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Olistico Wealth LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer during the 2nd quarter valued at about $29,000. Quarry LP acquired a new stake in Pfizer in the 2nd quarter valued at about $31,000. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth approximately $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.6 %

PFE opened at $29.16 on Friday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $33.92. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $29.04 and a 200-day simple moving average of $28.38. The firm has a market cap of $165.24 billion, a P/E ratio of -486.00, a P/E/G ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the business posted $0.67 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.76%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is currently -2,800.00%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PFE. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Thursday, October 3rd. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Barclays boosted their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.